Etelcalcetide
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](http://data.docslib.org/img/264x/135084d885a0ce0d8ef8f9f83426c79a.webp)
Top View
- Parsabiv H-3995
- One-Year Safety and Efficacy of Intravenous Etelcalcetide in Patients on Hemodialysis with Secondary Hyperparathyroidism
- Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide
- Product List
- Pharmacoeconomic Evaluation of Antibiotic Therapy of Community
- New Drugs 2018, Part 3
- Parsabiv™ (Etelcalcetide)
- Etelcalcetide, a Novel Synthetic, D-Amino Acid Peptide
- Advancements and Technologies Driving Peptide Drug Design and Development
- Calcimimetic (Cinacalcet, Etelcalcetide) Criteria for Use January 2018
- CP.PHAR.379 Etelcalcetide (Parsabiv)
- Effect of Etelcalcetide Vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism a Randomized Clinical Trial
- Parsabiv Generic Name2,4: Etelcalcetide Manufacturer4
- Advances in Therapeutic Peptides Targeting G Protein-Coupled Receptors
- Etelcalcetide for Treating Secondary Hyperparathyroidism 1 Recommendations
- Seres's Pioneering Microbiome Drug Fails Mid-Stage Trial
- Report on the Deliberation Results November 14, 2016
- ― D06 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版（ 2019） カテゴリー別リスト